Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-019707
Filing Date
2022-03-17
Accepted
2022-03-17 17:43:14
Documents
1
Period of Report
2022-03-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3678
  Complete submission text file 0001209191-22-019707.txt   5030
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address
Sjuts Dustin S (Reporting) CIK: 0001796224 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36297 | Film No.: 22750096